This website is intended for US Healthcare Professionals.

CONTact Your MSL
Back to Congresses

AACR-iCML 2024

  • June 19 -
  • 22, 2024
  •  |
  • Philadelphia, PA

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Poster
Trial in Progress: Phase 1 Study of ARV-393, a PROteolysis TArgeting Chimera (PROTAC) B-Cell Lymphoma 6Degrader, in Advanced Non-Hodgkin Lymphoma
PF Caimi et al.
View Material

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP